Loading...
Carcinoid tumors represent a subset of neuroendocrine cancers that usually arise in the bowel or lung and are often associated with the serotonin-mediated carcinoid syndrome. Although these cancers are often indolent in growth, most patients with metastatic disease die within 5 years. Octreotide long-acting repeatable (LAR) is the mainstay of treatment for symptoms of carcinoid syndrome, and recent trials indicate that this agent might induce antitumor responses and improve progression-free survival (PFS). Conversely, chemotherapy is inactive in this disease, and, beyond octreotide LAR and interferon, no viable systemic therapy options exist. However, everolimus — an inhibitor of the mammalian target of rapamycin (mTOR) — was recently appro…